Klotho Neurosciences ( (KLTO) ) has shared an announcement.
Dr. Joseph Sinkule, the CEO, has secured a new three-year contract with a $360,000 annual salary and 1,000,000 stock options, aligning with the company’s 2023 Incentive Plan. These options have a three-year validity, priced at the stock’s closing rate on October 24, 2024, and he is eligible for the executive bonus program. This move could impact the company’s stock dynamics with potential strategic leadership continuity.
See more insights into KLTO stock on TipRanks’ Stock Analysis page.
